Wang C.-C.Chang J.-Y.Liu T.-W.Lin C.-Y.Yu Y.-C.RUEY-LONG HONG2021-03-092021-03-0920061043-3074https://www.scopus.com/inward/record.uri?eid=2-s2.0-30744470386&doi=10.1002%2fhed.20310&partnerID=40&md5=1bc85ea3638c091878fc8efff0f386f3https://scholars.lib.ntu.edu.tw/handle/123456789/551256Background. A phase II study was conducted to evaluate the safety and efficacy of a gemcitabine plus vinorelbine combination (GV) for patients with cisplatin-resistant nasopharyngeal carcinoma (NPC). Methods. Thirty-nine eligible patients received vinorelbine, 20 mg/m2, followed by gemcitabine, 1000 mg/m2, on days 1 and 8 of each 21-day cycle. Results. Grade 3/4 neutropenia and thrombocytopenia occurred in 44% and 18% of patients, respectively, but there was only one episode of febrile neutropenia. Nonhematologic toxicities were mild and did not lead to any treatment withdrawal. The overall response rate was 36% (95% confidence interval [Cl], 20% to 52%) in an intent-to-treat analysis, with one complete response (3%) and 13 partial responses (33%). The median response duration, progression-free survival, and overall survival were 5.1, 5.6, and 11.9 months, respectively. Conclusion. Given the moderately high activity and favorable toxicity profile, GV is a reasonable choice for patients with cisplatin-resistant NPC. ? 2005 Wiley Periodicals, Inc.Cisplatin resistant; Gemcitabine; Nasopharyngeal carcinoma; Salvage chemotherapy; Vinorelbine[SDGs]SDG3cisplatin; dexamethasone; gemcitabine; metoclopramide; navelbine; adult; aged; alopecia; anemia; anorexia; arthralgia; article; asthenia; cancer survival; clinical article; clinical trial; confidence interval; constipation; controlled clinical trial; controlled study; diarrhea; disease activity; disease course; drug efficacy; drug eruption; drug fever; drug safety; drug treatment failure; fatigue; febrile neutropenia; female; human; human tissue; infection; leukopenia; liver dysfunction; male; myalgia; nasopharynx carcinoma; nausea; neutropenia; phase 2 clinical trial; phlebitis; priority journal; stomatitis; thrombocytopenia; toxicity; treatment outcome; vomiting; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Treatment Outcome; Vinblastinejournal article10.1002/hed.20310163316922-s2.0-30744470386